MPN Patient Advocacy Works
Inspiring, tenacious and rewarding work that will benefit the lives of so many. Australian MPN patients can now have affordable access to Pegasys. This is the kind of success I would like to see happen around the globe. It takes a lot of time, effort, and dedication. Bravo Nathalie, I’m so proud of you and the […]
ASH Partners with UNC, a ClinGen grantee to Curate Genomic data for Blood Research
Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect that this project will lead to better understanding of MPNs in the future.” Thanks to the American Society of Hematology for being the source for this article. While this […]
Ruxolitinib Metformin combo: A Possible Alternative Treatment for Myeloproliferative Neoplasm Patients
Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease. The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces a complete response. Data from previous studies […]
How MPN Blood Cancers outsmart the Immune System
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their findings reveal that a subset of MPNs might be susceptible to treatment with immune checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway (a signaling network that normally functions as […]
Imago BioSciences gets FDA Approval of IND Application for Treatment of Myelofibrosis, IMG-7289 in Clinical Trials
Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their Investigational New Drug (IND) application providing clearance to proceed with the clinical development of IMG-7289 in the U.S. The IND supports the company’s ongoing Phase 1/2 clinical trial of […]
Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline
Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval […]
ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said […]
What is an MPN Specialist?
A Few Simple Criteria If your doctor has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world, and never published a peer-reviewed research paper, he or she isn’t likely to be an MPN specialist. Also, if their bio lists 12+ clinical interests, their focus is NOT likely […]
Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients with polycythemia […]
Dr Ruben Mesa, MPN Specialist named new director of University Texas Health Care Cancer Center in San Antonio
2023 Update – Dr. Ruben Mesa named to Lead Atrium Health Cancer Program Publisher’s Note (David Wallace) As a Charlotte native, I’m really excited to witness the tremendous growth of our world-class cancer centers along with the groundbreaking of Charlotte’s first 4-year medical school. The school is part of the Pearl CLT innovation district. The […]
A New Therapeutic Target for Myelofibrosis is cause for Gli
Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone marrow fibrosis (BMF), characterized by deposition of reticulin and collagen fibers in the marrow, is a hallmark of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs). PMF is characterized […]
Understanding Polycythemia Vera
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called Myeloproliferative Neoplasms (MPNs). PV […]
